Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet Drug Trial in Coronary Disease Progression
NCT00000496Phase 3
Key facts
- Status
- Completed
- Start
- Dec 1979
- Sponsor
- National Heart, Lung, and Blood Institute
- Modality
- Orthosteric Ligands
- Drugs
- dipyridamoleaspirin
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 3, randomised, double-blind trial in coronary artery disease (CAD) comparing Dipyridamole + Aspirin with Placebo (2 arms). Primary endpoints: Angiographic evidence of progression of coronary artery disease at 5 years and Development of new coronary disease at 5 years. Started Dec 1979; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Dipyridamole + Aspirin
Dipyridamole and Aspirin
Placebo
Lactose Placebo
03
Who it enrols
Patients aged 65 or less with angiographically identified coronary heart disease.
04
Endpoints
Primary
Angiographic evidence of progression of coronary artery disease
Development of new coronary disease
Secondary
Total mortality
Cardiac mortality
Mortality due to myocardial infarction
Incidence of new myocardial infarction
Beyond the preview
Go deeper on NCT00000496.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000496.